Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study

Published:2023-05-18 Issue:1 Volume:12 Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Yan Vincent Ka Chun¹,Wan Eric Yuk Fai¹²³,Ye Xuxiao¹,Mok Anna Hoi Ying³,Lai Francisco Tsz Tsun¹²^ORCID,Chui Celine Sze Ling²⁴⁵,Li Xue¹²⁶,Wong Carlos King Ho¹²³,Li Philip Hei⁶,Ma Tiantian¹²,Qin Simon¹²,Lau Chak Sing⁶,Wong Ian Chi Kei¹²⁷⁸⁹,Chan Esther Wai Yin¹²⁹¹⁰

Affiliation:

1. Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Centre for Safe Medication Practice and Research, The University of Hong Kong, Hong Kong, People’s Republic of China

2. Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, People’s Republic of China

3. Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China

4. School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China

5. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China

6. Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China

7. Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK

8. Aston Pharmacy School, Aston University, Birmingham, UK

9. Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, People’s Republic of China

10. The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, People’s Republic of China

Funder

Food and Health Bureau

of the

Government of the Hong Kong Special Administrative Region

Hong Kong Research Grants Council

RGC Postdoctoral Fellowship

Hong Kong Research Grant Council

Hong Kong Innovation and Technology Commission

Pfizer

IQVIA

Amgen

PrimeVigilance

and Health Bureau

Janssen

University of Hong Kong

Merck Sharp & Dohme

Bristol Myers Squibb

Bayer

GSK

Novartis

Hong Kong Health and Medical Research Fund

National Institute for Health Research in England

European Commission

National Health and Medical Research Council in Australia

Research Grants Council

Research Fund Secretariat of the Food and Health Bureau

National Natural Science Fund of China

Wellcome Trust

Bristol-Myers Squibb

Takeda

Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region

Hospital Authority

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2023.2209201

Reference38 articles.

1. Coronavirus Resource Center of the Johns Hopkins University School of Medicine. Understanding vaccination progress by country 2022 [29 Apr 2022]. Available from: https://coronavirus.jhu.edu/vaccines/international.

2. HKSAR Government. Latest situation of reported cases of COVID-19 in Hong Kong 2022 [16 Apr 2022]. Available from: http://www.chp.gov.hk/files/misc/latest_situation_of_reported_cases_covid_19_eng.csv.

3. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan;Li C;Nat Commun,2021

4. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

5. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for long-term cardiovascular post-acute sequelae of COVID-19 infection: A nested case-control study in Hong Kong;npj Cardiovascular Health;2024-08-02

2. Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak;Human Vaccines & Immunotherapeutics;2024-06-21

3. Clinical and virological features of asymptomatic and mild symptomatic patients with SARS‐CoV‐2 Omicron infection at Shanghai Fangcang shelter hospital;Immunity, Inflammation and Disease;2023-09

4. Post-acute sequelae of COVID-19 in older persons: multi-organ complications and mortality;Journal of Travel Medicine;2023-06-13